Literature DB >> 7592741

4-(Fluoromethyl)phenyl phosphate acts as a mechanism-based inhibitor of calcineurin.

T L Born1, J K Myers, T S Widlanski, F Rusnak.   

Abstract

The compound 4-(fluoromethyl)phenyl phosphate (FMPP), recently shown to be a mechanism-based inhibitor of prostatic acid phosphatase (Myers, J.K., and Widlanski, T.S. (1993) Science 262, 1451-1453), was examined for its effect on calcineurin. This compound inhibits calcineurin in a time-dependent, first order manner. Inactivation with [3H]FMPP led to a specific labeling of the catalytic subunit with a stoichiometry of 0.75 mol of label/mol of protein. A related substrate, 4-methylphenyl phosphate, is able to protect calcineurin from FMPP-mediated inhibition. Scavenging nucleophiles, such as cysteine, do not affect the rate of inhibition when included in the reaction. In addition, extensive dialysis indicates that inhibition is essentially irreversible. These results demonstrate that FMPP inactivates calcineurin in a mechanism-based fashion by forming a covalent adduct with calcineurin A, the catalytic subunit.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7592741     DOI: 10.1074/jbc.270.43.25651

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Activity-based probes for protein tyrosine phosphatases.

Authors:  Sanjai Kumar; Bo Zhou; Fubo Liang; Wei-Qing Wang; Zhonghui Huang; Zhong-Yin Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-17       Impact factor: 11.205

2.  Evaluation of sulfatase-directed quinone methide traps for proteomics.

Authors:  Janina Lenger; Marius Schröder; Eva C Ennemann; Benjamin Müller; Chi-Huey Wong; Thomas Noll; Thomas Dierks; Sarah R Hanson; Norbert Sewald
Journal:  Bioorg Med Chem       Date:  2011-04-24       Impact factor: 3.641

Review 3.  Covalent inhibition of protein tyrosine phosphatases.

Authors:  Kasi Viswanatharaju Ruddraraju; Zhong-Yin Zhang
Journal:  Mol Biosyst       Date:  2017-06-27

4.  Nitrates and NO-NSAIDs in cancer chemoprevention and therapy: in vitro evidence querying the NO donor functionality.

Authors:  Tareisha Dunlap; Samer O Abdul-Hay; R Esala P Chandrasena; Ghenet K Hagos; Vaishali Sinha; Zhiqiang Wang; Huali Wang; Gregory R J Thatcher
Journal:  Nitric Oxide       Date:  2008-04-23       Impact factor: 4.427

5.  Use of Fluorinated Functionality in Enzyme Inhibitor Development: Mechanistic and Analytical Advantages.

Authors:  David B Berkowitz; Kannan R Karukurichi; Roberto de la Salud-Bea; David L Nelson; Christopher D McCune
Journal:  J Fluor Chem       Date:  2008-09       Impact factor: 2.050

6.  Novel inhibitors of the calcineurin/NFATc hub - alternatives to CsA and FK506?

Authors:  Matthias Sieber; Ria Baumgrass
Journal:  Cell Commun Signal       Date:  2009-10-27       Impact factor: 5.712

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.